Celsion Announces Progression-Free Survival Data From GEN-1 Phase I Immuno-Oncology Study of Patients with Stage III/IV Ovarian Cancer
24. Oktober 2018 09:25 ET
|
Celsion CORP
Single Arm Study Demonstrated a Median Progression-Free Survival (PFS) of 24.3 Months for Patients Treated per Protocol; Patients in the Intent-to-Treat Population had a Median PFS of 17.1 months...